Maze Therapeutics

Edit info

Founded: 2019

Location: South SF, CA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Pompe disease (partner: Sanofi)

Drug types: RAR, GEN, MUS, NPH, CVV, NEU, OPH, GER

Lead product: MZE001

Funding: $190M Jan 2022; $191M Feb 2019

Investors: Third Rock, Arch

mazetx.com

linkedin.com

job board

Business:

Small Molecules, Gene Therapy, Antisense Oligonucleotides, Biologics

Drug notes:

Undisclosed programs RD/Clin0 kidney diseases, cardiovascular condition, ALS, glaucoma, AMD

About:

Maze therapeutics is translating genetic insights into new medicines. Advances in human genome sequencing and functional genomics now offer the chance to decode the mysteries of the genetics of disease. Maze is exploiting these advances to map novel connections between known genes and disease. Maze navigates genetic diversity with their proprietary Compass platform that combines human genetic data, functional genomics tools and data science technology. Maze is leveraging Compass for target identification, drug discovery and drug development to unlock the central tenet of precision medicine: to deliver the right drug, to the right patient, at the right time. Maze is currently pursuing programs in metabolic, cardiovascular and renal diseases.